UNASSIGNED: e19543 Background: Bevacizumab has been associated with @entity715 events in @entity5 @entity1 , but results from recent pooled analyses of clinical trials have produced conflicting data. METHODS: Data were extracted from the IMS @entity1 -Centric Database of commercially insured @entity1 in the United States. Demographics/clinical characteristics of ambulatory adult @entity1 with @entity5 who were initiating chemotherapy (n=17,284) and a matched control cohort without @entity5 (n=17,284) were evaluated. Incidence of @entity1211 ( @entity1211 ), @entity548 , resource utilization, and cost were recorded during a follow-up period of 3-12 months after initiation of chemotherapy in the @entity5 cohort. Data from the entire @entity5 cohort and sub-cohort with @entity14 only were analyzed. RESULTS: Overall, 2,170 (12.6%) @entity1 experienced @entity1211 in the @entity5 cohort compared with 237 (1.4%) in the control cohort (P<0.0001). The incidence of @entity1211 events among @entity5 @entity1 included 7.7% (n=1,336) deep vein @entity715 , 2.4% (n=406) @entity1151 , and 2.5% (n=428) both. The respective @entity548 rates were 22.4% (n=3,873) and 7.0% (n=1,211; P<0.0001). Among @entity1 with @entity5 , 11.8% (n=2,035) received bevacizumab. @entity1 treated with bevacizumab had a significantly increased risk of any @entity1211 event (odds ratio [OR], 1.43; 95% confidence interval [CI], 1.24, 1.65; P<0.0001) and @entity548 (OR, 1.39; 95% CI, 1.23, 1.57; P<0.0001) compared with @entity1 not treated with bevacizumab. Of 4,548 @entity1 with @entity14 , 480 (10.6%) experienced @entity1211 ; 1,135 (25.0%) received bevacizumab. @entity14 @entity1 treated with bevacizumab had a significantly increased risk of @entity1211 (OR, 1.66; 95% CI, 1.32, 2.10; P<0.0001) and @entity548 (OR, 1.51; 95% CI, 1.24, 1.83; P<0.0001) compared with those not treated with bevacizumab. CONCLUSIONS: The risk of @entity1211 was high among this cohort of ambulatory @entity1 with @entity5 and sub-cohort of @entity1 with @entity14 . The incidence of @entity1211 and @entity548 was increased further in those who were treated with bevacizumab. Study funding and editorial support provided by sanofi-aventis U.S.

Does bevacizumab increase the risk of XXXX ? A cohort study.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'Patient'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity1151 :: ('MESH:D011655', 'Disease') :: ['pulmonary embolism'] @entity14 :: ('MESH:D015179', 'Disease') :: ['Colorectal cancer', 'colorectal cancer'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis', 'thrombotic'] @entity1211 :: ('MESH:D054556', 'Disease') :: ['VTE', 'venous thromboembolism']
@entity1211 :: (MESH:D054556,Disease) :: ['venous thromboembolism']
